Phospholipase A₂ inhibitors for the treatment of inflammatory diseases: a patent review (2010 – present)

Bibliography

• Dennis EA, Cao J, Hsu YH, Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 2011;111:6130-85
   PubMed Web of Science ®Google Scholar
• Kramer RM, Hession C, Johansen B, Structure and properties of a human non-pancreatic phospholipase A2. J Biol Chem 1989;264:5768-75
   PubMed Web of Science ®Google Scholar
• Seilhamer JJ, Pruzanski W, Vadas P, Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem 1989;264:5335-8
   PubMed Web of Science ®Google Scholar
• Clark JD, Lin LL, Kriz RW, A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell 1991;65:1043-51
   PubMed Web of Science ®Google Scholar
• Kramer RM, Roberts EF, Manetta J, The Ca2+-sensitive cytosolic phospholipase A2 is a 100-kDa protein in human monoblast U937 cells. J Biol Chem 1991;266:5268-72
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Kempner ES, Dennis EA. Ca2+-independent cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization. J Biol Chem 1994;269:9227-33
   PubMed Web of Science ®Google Scholar
• Stafforini DM, Elstad MR, McIntyre TM, Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 1990;265:9682-7
   PubMed Web of Science ®Google Scholar
• Tjoelker LW, Wilder C, Eberhardt C, Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549-53
   PubMed Web of Science ®Google Scholar
• Lehr M. Phospholipase A2 inhibitors in inflammation. Expert Opin Ther Pat 2001;11:1123-36
   Web of Science ®Google Scholar
• Clark JD, Tam S. Potential therapeutic uses of phospholipase A2 inhibitors. Expert Opin Ther Pat 2004;14:937-50
   Web of Science ®Google Scholar
• Magrioti V, Kokotos G. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opin Ther Pat 2010;20:1-18
   PubMed Web of Science ®Google Scholar
• Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 2008;77:495-520
   PubMed Web of Science ®Google Scholar
• Murakami M, Taketomi Y, Girard C, Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. Biochimie 2010;92:561-82
   PubMedGoogle Scholar
• Murakami M, Taketomi Y, Sato H, Secreted phospholipase A2 revisited. J Biochem 2011;150:233-55
   Google Scholar
• Murakami M, Lambeau G. Emerging roles of secreted phospholipase A2 enzymes: An update. Biochimie 2012;92(6):561-82
   Google Scholar
• Thompson W, Oslund RC, Bollinger J, High-throughput assay of secreted phospholipases A2 inhibitors. Methods Mol Biol 2012;861:149-58
   PubMedGoogle Scholar
• Boilard E, Lai Y, Larabee K, A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med 2010;2:172-87
   PubMedGoogle Scholar
• Rosenson RS, Gelb MH. Secretory phospholipase A2: A multifaceted family of proatherogenic enzymes. Curr Cardiol Rep 2009;11:445-51
   PubMedGoogle Scholar
• Kugiyama K, Ota Y, Takazoe K, Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280-4
   PubMed Web of Science ®Google Scholar
• Cai Q, Zhao Z, Antalis C, Elevated and secreted phospholipase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB J 2012;26:3306-20
   PubMedGoogle Scholar
• University of Cincinnati. Serum sPLA2-IIA as diagnosis marker for prostate and lung cancer. WO2011085002; 2011
   Google Scholar
• http://clinicaltrials.gov/ Identifier: NCT00034476
   Google Scholar
• Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (sPLA2) inhibitors and sPLA2 inhibitor combination therapies. WO2008137803; 2008
   Google Scholar
• Anthera Pharmaceuticals Inc. Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase A2 (sPLA2) inhibitor or sPLA2 inhibitor combination therapies. WO2010071854; 2010
   Google Scholar
• Anthera Pharmaceuticals Inc. Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase A2 (sPLA2) inhibitor or sPLA2 inhibitor combination therapies. WO2011137390; 2011
   Google Scholar
• Anthera Pharmaceuticals Inc. Secretory phospholipase A2 (sPLA2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia. WO2010081022; 2010
   Google Scholar
• Anthera Pharmaceuticals Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (sPLA2) inhibitors or sPLA2 inhibitor combination therapies. US20110207710; 2011
   Google Scholar
• http://clinicaltrials.gov/ Identifier: NCT00743925
   Google Scholar
• http://clinicaltrials.gov/ Identifier: NCT01130246
   Google Scholar
• Hallstrand TS, Lai Y, Ni Z, Relationship between levels of secreted phospholipase A2 groups IIA and X in the airways and asthma severity. Clin Exp Allergy 2011;41:801-10
   PubMed Web of Science ®Google Scholar
• Henderson WR Jr, Oslund RC, Bollinger JG, Blockade of human group X secreted phospholipase A2 (GX-sPLA2)-induced airway inflammation and hyperresponsiveness in a mouse asthma model by a selective GX-sPLA2 inhibitor. J Biol Chem 2011;286:28049-55
   PubMed Web of Science ®Google Scholar
• Mouchlis VD, Mavromoustakos TM, Kokotos G. Molecular docking and 3D-QSAR CoMFA studies on indole inhibitors of GIIA secreted phospholipase A2. J Chem Inf Model 2010;50:1589-601
   PubMed Web of Science ®Google Scholar
• The Regents of the University of California. Amides as inhibitors of human secreted phospholipase A2. WO2010011686; 2010
   Google Scholar
• Antonopoulou G, Barbayianni E, Magrioti V, Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A2 enzymes. Bioorg Med Chem 2008;16:10257-69
   PubMedGoogle Scholar
• Iyer A, Lim J, Poudyal H, An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats. Diabetes 2012;61:2320-9
   PubMedGoogle Scholar
• Saint Louis University. Compositions and methods for the treatment of sepsis and other disorders involving phospholipase A2 induction. WO2010123648; 2010
   Google Scholar
• Alonso F, Henson PM, Leslie CC. A cytosolic phospholipase in human neutrophils that hydrolyzes arachidonoyl-containing phosphatidylcholine. Biochim Biophys Acta 1986;878:273-80
   PubMedGoogle Scholar
• Kramer RM, Checani GC, Deykin A, Solubilization and properties of Ca2+-dependent human platelet phospholipase A2. Biochim Biophys Acta 1986;878:394-403
   PubMed Web of Science ®Google Scholar
• Tay A, Simon JS, Squire J, Cytosolic phospholipase A2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics 1995;26:138-41
   PubMedGoogle Scholar
• Channon JY, Leslie CC. A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7. J Biol Chem 1990;265:5409-13
   PubMedGoogle Scholar
• Gijon MA, Spencer DM, Kaiser AL, Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2. J Cell Biol 1999;145:1219-32
   PubMed Web of Science ®Google Scholar
• Sharp JD, Pickard RT, Chiou XG, Serine 228 is essential for catalytic activities of 85-kDa cytosolic phospholipase A2. J Biol Chem 1994;269:23250-4
   PubMed Web of Science ®Google Scholar
• Huang Z, Payette P, Abdullah K, Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2. Biochemistry 1996;35:3712-21
   PubMed Web of Science ®Google Scholar
• Xu GY, McDonagh T, Yu HA, Solution structure and membrane interactions of the C2 domain of cytosolic phospholipase A2. J Mol Biol 1998;280:485-500
   PubMed Web of Science ®Google Scholar
• Dessen A, Tang J, Schmidt H, Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell 1999;97:349-60
   PubMed Web of Science ®Google Scholar
• Uozumi N, Kume K, Nagase T, Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 1997;390:618-22
   PubMed Web of Science ®Google Scholar
• Bonventre JV, Huang Z, Taheri MR, Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 1997;390:622-5
   PubMed Web of Science ®Google Scholar
• Nagase T, Uozumi N, Ishii S, Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nat Immunol 2000;1:42-6
   PubMed Web of Science ®Google Scholar
• Nakanishi M, Rosenberg DW. Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta 2006;1761:1335-43
   PubMed Web of Science ®Google Scholar
• Caiazza F, Harvey BJ, Thomas W. Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth. Mol Endocrinol 2010;24:953-68
   PubMedGoogle Scholar
• Caiazza F, McCarthy NS, Young L, Cytosolic phospholipase A2alpha expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. Br J Cancer 2011;104:338-44
   PubMedGoogle Scholar
• Patel MI, Singh J, Niknami M, Cytosolic phospholipase A2alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res 2008;14:8070-9
   PubMed Web of Science ®Google Scholar
• Sundarraj S, Kannan S, Thangam R, Effects of the inhibition of cytosolic phospholipase A2a in non-small cell lung cancer cells. J Cancer Res Clin Oncol 2012;138:827-35
   PubMedGoogle Scholar
• Sanchez-Mejia RO, Newman JW, Toh S, Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 2008;11:1311-18
   PubMed Web of Science ®Google Scholar
• Gentile M, Reccia M, Sorrentino P, Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis. Mol Neurobiol 2012;45:596-604
   PubMedGoogle Scholar
• Wyeth Corp. Inhibitors of cytosolic phospholipase A2. WO03048122; 2003
   Google Scholar
• Wyeth Corp. Methods for treating asthmatic conditions. US2003149029; 2003
   Google Scholar
• Wyeth Corp. Inhibitors of cytosolic phospholipase A2. WO2006128142; 2006
   Google Scholar
• Wyeth Corp. Methods for the use of inhibitors of cytosolic phospholipase A2. US2006014759; 2006
   Google Scholar
• Lee KL, Foley MA, Chen L, Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha. J Med Chem 2007;50:1380-400
   PubMed Web of Science ®Google Scholar
• McKew JC, Lee KL, Shen MW, Indole cytosolic phospholipase A2alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. J Med Chem 2008;51:3388-413
   PubMed Web of Science ®Google Scholar
• Nickerson-Nutter CL, Goodwin D, Shen MW, The cPLA2alpha inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid. Neuropharmacology 2011;60:633-41
   PubMedGoogle Scholar
• http://clinicaltrials.gov/ Identifier: NCT00396955
   Google Scholar
• Seno K, Okuno T, Nishi K, Pyrrolidine inhibitors of human cytosolic phospholipase A2. J Med Chem 2000;43:1041-4
   PubMed Web of Science ®Google Scholar
• Twincore zentrum fuer experimentelle und klinische infektionsforschung GMBH and Ruprecht-Karls Universitat Heidelberg. Use of inhibitors of phospholipase A2 for the treatment or prevention of flavivirus infection. WO2012031763; 2012
   Google Scholar
• Menzel N, Fischl W, Hueging K, MAP-Kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious Hepatitis C virus particles. PLoS Pathog 2012;8:e1002829
   PubMed Web of Science ®Google Scholar
• Bovens S, Schulze Elfringhoff A, Kaptur M, 1-(5-carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2alpha: Effect of substituents in position 3 of the indole scaffold on inhibitory potency, metabolic stability, solubility, and bioavailability. J Med Chem 2010;53:8298-308
   PubMed Web of Science ®Google Scholar
• Drews A, Bovens S, Roebrock K, 1-(5-carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2alpha with reduced lipophilicity: Synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity. J Med Chem 2010;53:5165-78
   PubMed Web of Science ®Google Scholar
• Kaptur M, Elfringhoff AS, Lehr M. Structure-activity relationship studies on 1-(5-carboxyindol-1-yl)-propan- 2-one inhibitors of human cytosolic phospholipase A2alpha: Variation of the activated ketone moiety. Bioorg Med Chem Lett 2011;21:1773-6
   PubMed Web of Science ®Google Scholar
• Westfalische Wilhelms Universitat Munster. Novel heteroaryl-substituted acetone derivative, suitable for inhibiting phospholipase A2. WO2009040314; 2009
   Google Scholar
• Forster L, Ludwig J, Kaptur M, 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A2alpha and fatty acid amide hydrolase. Bioorg Med Chem 2010;18:945-52
   PubMed Web of Science ®Google Scholar
• Zahov S, Drews A, Hess M, 1-(3-Biaryloxy-2-oxopropyl)indole-5-carboxylic Acids and Related Compounds as Dual Inhibitors of Human Cytosolic Phospholipase A2alpha and Fatty Acid Amide Hydrolase. ChemMedChem 2011;6:544-9
   PubMed Web of Science ®Google Scholar
• Roebrock K, Wolf M, Bovens S, Inhibition of benzalkonium chloride-induced skin inflammation in mice by an indol-1-ylpropan-2-one inhibitor of cytosolic phospholipase A2alpha. Br J Dermatol 2012;166:306-16
   PubMed Web of Science ®Google Scholar
• The Regents of the University of California. Phospholipase A2 inhibitors and their use in treating neurological injury and disease. WO2009009449; 2009
   Google Scholar
• Kokotos G, Six DA, Loukas V, Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivo. J Med Chem 2004;47:3615-28
   PubMed Web of Science ®Google Scholar
• Yaksh TL, Kokotos G, Svensson CI, Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release. J Pharmacol Exp Ther 2006;316:466-75
   PubMed Web of Science ®Google Scholar
• Stephens D, Barbayianni E, Constantinou-Kokotou V, Differential inhibition of Group IVA and Group VIA phospholipases A2 by 2-oxoamides. J Med Chem 2006;49:2821-8
   PubMed Web of Science ®Google Scholar
• Six DA, Barbayianni E, Loukas V, Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2. J Med Chem 2007;50:4222-35
   PubMed Web of Science ®Google Scholar
• Lopez-Vales R, Ghasemlou N, Redensek A, Phospholipase A2 superfamily members play divergent roles after spinal cord injury. FASEB J 2011;25:4240-52
   PubMed Web of Science ®Google Scholar
• The Regents of the University of California. 2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides. WO2010123832; 2010
   Google Scholar
• Avexxin AS. Anti inflammatory 2-oxothiazole and 2-oxooxazoles. WO2011039365; 2011
   Google Scholar
• Mete A, Andrews G, Bernstein M, Design of novel and potent cPLA2alpha inhibitors containing an alpha-methyl-2-ketothiazole as a metabolically stable serine trap. Bioorg Med Chem Lett 2011;21:3128-33
   PubMedGoogle Scholar
• Tang J, Kriz RW, Wolfman N, A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. J Biol Chem 1997;272:8567-75
   PubMed Web of Science ®Google Scholar
• Balboa MA, Balsinde J, Jones SS, Identity between the Ca2+-independent phospholipase A2 enzymes from P388D1 macrophages and Chinese hamster ovary cells. J Biol Chem 1997;272:8576-80
   PubMedGoogle Scholar
• Lio YC, Dennis EA. Interfacial activation, lysophospholipase and transacylase activity of group VI Ca2+-independent phospholipase A2. Biochim Biophys Acta 1998;1392:320-32
   PubMed Web of Science ®Google Scholar
• Hazen SL, Zupan LA, Weiss RH, Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A2 - Mechanism-based discrimination between calcium-dependent and calcium-independent phospholipases A2. J Biol Chem 1991;266:7227-32
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Condefrieboes K, Dennis EA. Inhibition of macrophage Ca2+-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J Biol Chem 1995;270:445-50
   PubMed Web of Science ®Google Scholar
• Lei X, Barbour SE, Ramanadham S. Group VIA Ca2+-independent phospholipase A2 (iPLA2beta) and its role in beta-cell programmed cell death. Biochimie 2010;92:627-37
   PubMed Web of Science ®Google Scholar
• Lei X, Zhang S, Emani B, A link between endoplasmic reticulum stress-induced beta-cell apoptosis and the group VIA Ca2+-independent phospholipase A2 (iPLA2beta). Diabetes Obes Metab 2010;12:93-8
   PubMedGoogle Scholar
• Song Y, Wilkins P, Hu W, Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem J 2007;406:427-36
   PubMed Web of Science ®Google Scholar
• Malhotra A, Edelman-Novemsky I, Xu Y, Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome. P Natl Acad Sci USA 2009;106:2337-41
   PubMed Web of Science ®Google Scholar
• Poulsen KA, Pedersen SF, Kolko M, Induction of group VIA phospholipase A2 activity during in vitro ischemia in C2C12 myotubes is associated with changes in the level of its splice variants. Am J Physiol Cell Physiol 2007;293:C1605-15
   Google Scholar
• Andersen AD, Poulsen KA, Lambert IH, HL-1 mouse cardiomyocyte injury and death after simulated ischemia and reperfusion: Roles of pH, Ca2+-independent phospholipase A2, and Na+/H+ exchange. Am J Physiol Cell Physiol 2009;296:C1227-42
   Google Scholar
• Kalyvas A, Baskakis C, Magrioti V, Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. Brain 2009;132:1221-35
   PubMed Web of Science ®Google Scholar
• Calderon LE, Liu S, Su W, iPLA2beta overexpression in smooth muscle exacerbates angiotensin II-induced hypertension and vascular remodeling. PLoS One 2012;7:e31850
   Google Scholar
• McGill University, University of Athens, University of California San Diego. Perfluoroketone compounds and uses thereof. WO2008122119; 2008
   Google Scholar
• Baskakis C, Magrioti V, Cotton N, Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem 2008;51:8027-37
   PubMed Web of Science ®Google Scholar
• Kokotos G, Hsu YH, Burke JE, Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem 2010;53:3602-10
   PubMed Web of Science ®Google Scholar
• Li H, Zhao Z, Antalis C, Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development. Am J Pathol 2011;179:452-61
   PubMedGoogle Scholar
• Paliege A, Roeschel T, Neymeyer H, Group VIA phospholipase A2 is a target for vasopressin signaling in the thick ascending limb. Am J Physiol Renal Physiol 2012;302:F865-74
   Google Scholar
• Stremler KE, Stafforini DM, Prescott SM, Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 1991;266:11095-103
   PubMed Web of Science ®Google Scholar
• MacPhee CH, Moores KE, Boyd HF, Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor. Biochem J 1999;338(Pt 2):479-87
   PubMed Web of Science ®Google Scholar
• Davis B, Koster G, Douet LJ, Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J Biol Chem 2008;283:6428-37
   PubMed Web of Science ®Google Scholar
• Tjoelker LW, Eberhardt C, Unger J, Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J Biol Chem 1995;270:25481-7
   PubMed Web of Science ®Google Scholar
• Hakkinen T, Luoma JS, Hiltunen MO, Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999;19:2909-17
   PubMed Web of Science ®Google Scholar
• Lavi S, Herrmann J, Lavi R, Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Curr Atheroscler Rep 2008;10:230-5
   PubMed Web of Science ®Google Scholar
• Caslake MJ, Packard CJ, Suckling KE, Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-19
   PubMed Web of Science ®Google Scholar
• Blake GJ, Dada N, Fox JC, A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38:1302-6
   PubMed Web of Science ®Google Scholar
• Gazi I, Lourida ES, Filippatos T, Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264-73
   PubMed Web of Science ®Google Scholar
• Winkler K, Hoffmann MM, Winkelmann BR, Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem 2007;53:1440-7
   PubMed Web of Science ®Google Scholar
• Anderson JL. Lipoprotein-associated phospholipase A2: An independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008;101:23F-33F
   Google Scholar
• Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A2 and atherosclerosis. Curr Opin Lipidol 2009;20:415-20
   PubMed Web of Science ®Google Scholar
• Casas JP, Ninio E, Panayiotou A, PLA2G7 Genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of european ancestry. Circulation 2010;121:2284-93
   PubMedGoogle Scholar
• Thompson A, Gao P, Orfei L, Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44
   PubMed Web of Science ®Google Scholar
• Hui DY. Phospholipase A2 enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol 2012;23:235-40
   PubMed Web of Science ®Google Scholar
• Smithkline Beecham PLC. Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors. WO0160805; 2001
   Google Scholar
• http://clinicaltrials.gov/ Identifier: NCT01067339
   Google Scholar
• http://clinicaltrials.gov/ Identifier: NCT01506895
   Google Scholar
• http://clinicaltrials.gov/ Identifier: NCT01711723
   Google Scholar
• Rongen RML, Kling D, Doyle RT Jr, Omega-3 fatty acids for reduction of LpPLA2 levels. US20110251275; 2011
   Google Scholar
• Smithkline Beecham PLC. Pyridinone derivatives for treatment of atherosclerosis. WO2002030904; 2002
   Google Scholar
• Auspex Pharmaceutics, Inc. Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2. US20110306552; 2011
   Google Scholar
• Auspex Pharmaceutics, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2. US20110136861; 2011
   Google Scholar
• Scott KF, Sajinovic M, Hein J, Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 2010;92:601-10
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang X, Yonz C, Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells. Biochem Pharmacol 2010;79:1727-35
   Google Scholar
• Song H, Wohltmann M, Tan M, Group VIA PLA2 (iPLA2beta) is activated upstream of p38 mitogen-activated protein kinase (MAPK) in pancreatic islet beta-cell signaling. J Biol Chem 2012;287:5528-41
   PubMed Web of Science ®Google Scholar
• Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011;10:365-76
   PubMed Web of Science ®Google Scholar
• David S, Greenhalgh AD, Lopez-Vales R. Role of phospholipase A2s and lipid mediators in secondary damage after spinal cord injury. Cell Tissue Res 2012;349:249-67
   PubMedGoogle Scholar
• Hewson CA, Patel S, Calzetta L, Preclinical evaluation of an inhibitor of cytosolic phospholipase A2alpha for the treatment of asthma. J Pharmacol Exp Ther 2012;340:656-65
   PubMed Web of Science ®Google Scholar
• Zhang J, Barasch N, Li RC, Inhibition of cytosolic phospholipase A2 alpha protects against focal ischemic brain damage in mice. Brain Res 2012;1471:129-37
   PubMedGoogle Scholar
• Saito Y, Watanabe K, Fujioka D, Disruption of group IVA cytosolic phospholipase A2 attenuates myocardial ischemia-reperfusion injury partly through inhibition of TNF-alpha-mediated pathway. Am J Physiol Heart Circ Physiol 2012;302:H2018-30
   PubMed Web of Science ®Google Scholar
• Burke JE, Babakhani A, Gorfe AA, Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry. J Am Chem Soc 2009;131:8083-91
   PubMed Web of Science ®Google Scholar
• Mouchlis VD, Michopoulou V, Constantinou-Kokotou V, Binding conformation of 2-oxoamide inhibitors to group IVA cytosolic phospholipase A2 determined by molecular docking combined with molecular dynamics. J Chem Inf Model 2012;52:243-54
   PubMedGoogle Scholar
• Noha SM, Jazzar B, Kuehnl S, Pharmacophore-based discovery of a novel cytosolic phospholipase A2alpha inhibitor. Bioorg Med Chem Lett 2012;22:1202-7
   PubMedGoogle Scholar